373 related articles for article (PubMed ID: 23407760)
1. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
Klein CJ; Lennon VA; Aston PA; McKeon A; O'Toole O; Quek A; Pittock SJ
JAMA Neurol; 2013 Feb; 70(2):229-34. PubMed ID: 23407760
[TBL] [Abstract][Full Text] [Related]
2. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
[TBL] [Abstract][Full Text] [Related]
3. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.
Lang B; Makuch M; Moloney T; Dettmann I; Mindorf S; Probst C; Stoecker W; Buckley C; Newton CR; Leite MI; Maddison P; Komorowski L; Adcock J; Vincent A; Waters P; Irani SR
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):353-361. PubMed ID: 28115470
[TBL] [Abstract][Full Text] [Related]
4. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
van Sonderen A; Schreurs MW; de Bruijn MA; Boukhrissi S; Nagtzaam MM; Hulsenboom ES; Enting RH; Thijs RD; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Neurology; 2016 May; 86(18):1692-9. PubMed ID: 27037230
[TBL] [Abstract][Full Text] [Related]
5. Detection of LGI1 and CASPR2 antibodies with a commercial cell-based assay in patients with very high VGKC-complex antibody levels.
Yeo T; Chen Z; Chai JYH; Tan K
J Neurol Sci; 2017 Jul; 378():85-90. PubMed ID: 28566186
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
7. Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia.
Vincent A; Pettingill P; Pettingill R; Lang B; Birch R; Waters P; Irani SR; Buckley C; Watanabe O; Arimura K; Kiernan MC
JAMA Neurol; 2018 Dec; 75(12):1519-1527. PubMed ID: 30242309
[TBL] [Abstract][Full Text] [Related]
8. Cramp-fasciculation syndrome in patients with and without neural autoantibodies.
Liewluck T; Klein CJ; Jones LK
Muscle Nerve; 2014 Mar; 49(3):351-6. PubMed ID: 23836298
[TBL] [Abstract][Full Text] [Related]
9. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
Michael S; Waters P; Irani SR
Pract Neurol; 2020 Oct; 20(5):377-384. PubMed ID: 32595134
[TBL] [Abstract][Full Text] [Related]
10. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.
Gadoth A; Pittock SJ; Dubey D; McKeon A; Britton JW; Schmeling JE; Smith A; Kotsenas AL; Watson RE; Lachance DH; Flanagan EP; Lennon VA; Klein CJ
Ann Neurol; 2017 Jul; 82(1):79-92. PubMed ID: 28628235
[TBL] [Abstract][Full Text] [Related]
11. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex.
Montojo MT; Petit-Pedrol M; Graus F; Dalmau J
Neurologia; 2015 Jun; 30(5):295-301. PubMed ID: 24485651
[TBL] [Abstract][Full Text] [Related]
12. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.
Binks SNM; Klein CJ; Waters P; Pittock SJ; Irani SR
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):526-534. PubMed ID: 29055902
[TBL] [Abstract][Full Text] [Related]
13. Chronic pain as a manifestation of potassium channel-complex autoimmunity.
Klein CJ; Lennon VA; Aston PA; McKeon A; Pittock SJ
Neurology; 2012 Sep; 79(11):1136-44. PubMed ID: 22895588
[TBL] [Abstract][Full Text] [Related]
14. Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia.
Kannoth S; Nambiar V; Gopinath S; Anandakuttan A; Mathai A; Rajan PK
Neurol Sci; 2018 Mar; 39(3):455-460. PubMed ID: 29264691
[TBL] [Abstract][Full Text] [Related]
15. From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time.
van Sonderen A; Schreurs MW; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Autoimmun Rev; 2016 Oct; 15(10):970-4. PubMed ID: 27485013
[TBL] [Abstract][Full Text] [Related]
16. Emerging psychiatric syndromes associated with antivoltage-gated potassium channel complex antibodies.
Prüss H; Lennox BR
J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1242-1247. PubMed ID: 27435086
[TBL] [Abstract][Full Text] [Related]
17. Morvan syndrome: clinical and serological observations in 29 cases.
Irani SR; Pettingill P; Kleopa KA; Schiza N; Waters P; Mazia C; Zuliani L; Watanabe O; Lang B; Buckley C; Vincent A
Ann Neurol; 2012 Aug; 72(2):241-55. PubMed ID: 22473710
[TBL] [Abstract][Full Text] [Related]
18. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.
van Sonderen A; Petit-Pedrol M; Dalmau J; Titulaer MJ
Nat Rev Neurol; 2017 May; 13(5):290-301. PubMed ID: 28418022
[TBL] [Abstract][Full Text] [Related]
19. Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy.
Lahoria R; Pittock SJ; Gadoth A; Engelstad JK; Lennon VA; Klein CJ
Muscle Nerve; 2017 Apr; 55(4):520-525. PubMed ID: 27511450
[TBL] [Abstract][Full Text] [Related]
20. LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome.
Nosadini M; Toldo I; Tascini B; Bien CG; Parmeggiani L; De Gaspari P; Zuliani L; Sartori S
J Neuroimmunol; 2019 Oct; 335():577008. PubMed ID: 31352183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]